Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
19.19
-0.83 (-4.15%)
At close: Jun 25, 2025, 4:00 PM
19.28
+0.09 (0.47%)
Pre-market: Jun 26, 2025, 6:46 AM EDT
Oscar Health Stock Forecast
Stock Price Forecast
The 5 analysts that cover Oscar Health stock have a consensus rating of "Hold" and an average price target of $16.5, which forecasts a -14.02% decrease in the stock price over the next year. The lowest target is $12 and the highest is $23.
Price Target: $16.5 (-14.02%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Oscar Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 3 | 3 | 3 | 1 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $25 → $18 | Buy | Maintains | $25 → $18 | -6.20% | Jun 9, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $20 → $16 | Buy → Hold | Downgrades | $20 → $16 | -16.62% | Mar 13, 2025 |
| Jefferies | Jefferies | Sell Initiates $12 | Sell | Initiates | $12 | -37.47% | Dec 10, 2024 |
| B of A Securities | B of A Securities | Hold → Sell Downgrades $21 → $14 | Hold → Sell | Downgrades | $21 → $14 | -29.65% | Nov 6, 2024 |
| UBS | UBS | Hold Initiates $23 | Hold | Initiates | $23 | +19.85% | Oct 7, 2024 |
Financial Forecast
Revenue This Year
11.55B
from 9.18B
Increased by 25.81%
Revenue Next Year
11.49B
from 11.55B
Decreased by -0.47%
EPS This Year
0.70
from 0.10
Increased by 603.80%
EPS Next Year
0.73
from 0.70
Increased by 4.35%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.5B | 13.3B | 14.9B |
| Avg | 11.5B | 11.5B | 13.3B |
| Low | 10.8B | 10.4B | 11.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 36.0% | 15.4% | 30.0% |
| Avg | 25.8% | -0.5% | 16.0% |
| Low | 18.0% | -9.8% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.92 | 1.12 | 2.36 |
| Avg | 0.70 | 0.73 | 1.67 |
| Low | 0.58 | 0.09 | 0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 824.0% | 59.6% | 221.7% |
| Avg | 603.8% | 4.3% | 127.8% |
| Low | 478.2% | -87.5% | -26.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.